Erenumab is a calcitonin-gene related peptide antagonist used to prevent migraines. Aimovig, as released and marketed by Novartis and Amgen, is in fact a novel therapeutic approach as the first and only FDA approved treatment specifically developed to prevent migraine by blocking the CGRP receptor, which...
- Mechanism
- Curator reviewed · 5 references
Erenumab is a human monoclonal antibody that has been designed to bind specifically to the calcitonin gene-related peptide (CGRP) receptor and antagonize the CGRP receptor function.
Studies since 1985 have demonstrated that CGRP levels increase during acute migraine attacks in migraine-suffering patients but normalize after efficacious sumatriptan therapy. Moreover, research has also shown that intravenous administration of CGRP can induce migraine-like attacks in migraine-suffering patients. For all these reasons, the binding and antagonism of CGRP receptors was designed to be mechanism of action for erenumab to take advantage of in reversing the migraine-inducing activity of natural CGRP.
CGRP and its receptor are expressed in both the peripheral and the central nervous system. In addition to playing a role in cranial nociception, CGRP is also a potent general arterial vasodilator. At peripheral synapses, CGRP released from trigeminal terminals results in vasodilation via CGRP receptors on the smooth muscle cells of meningeal and cerebral blood vessels.
- Primary indication
- Erenumab is indicated for the preventative treatment of migraine in adults.Curator reviewed · 1 structured indication
- Formula / weight
- C6472H9964N1728O2018S50
- First approval
- Canada, 2018 · United States, 2018 · European Union, 2020
- Also known as
- erenumab-aooe
- Code names
- AMG-334
- Brand names
Resolves to
What you can answer from here — as of November 28, 2024
Which drugs share a target with Erenumab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account